Positron Corporation (POSC)

[crammerfool]

dblue, I also noticed from Google Earth that IBA Eastern Isotopes, Inc is located in the same building as Positron Corp.

These do not necessarily relate to any new news, but something I found interesting in looking back on time. I found these links when I did a google search on IBA.

http://www.manta.com/c/mmc724c/iba-eastern-isotopes-inc


Here is another interesting thing I found on IBA and Positron.

http://stockreportcard.com/quote.php?symbol=POSC.OB
(found under Investor Relations - find it interesting that both Positron and IBA share the same building)

John Zehner, President Positron Radiopharmaceuticals, has over 14 years of experience in the Nuclear Medicine field. John has been part of several start-ups, mergers and acquisitions. In 1993, he assisted in the start-up of Northern Virginia Isotopes, Inc., a nuclear pharmacy focused on distributing radioactive pharmaceuticals for diagnostics and therapy to the Washington D.C. market. In 1994, he established Valley Isotopes, Inc., a nuclear pharmacy in Winchester, Virginia, Inc. In 1995, Mr. Zehner led the formation of Eastern Isotopes, Inc. through the merger of three nuclear pharmacies and later established its pharmaceutical manufacturing division for FDG in 1998. In 1999, he became President and COO of Eastern Isotopes, Inc. and under his leadership grew sales from approximately $4 million to over $34 million by 2003. In 200, Mr. Zehner formed NukeMed, Inc. and Dose Shield after leading the extremely lucrative sale of Eastern Isotopes, Inc. to IBA, SA, a Belgium life science company.

http://www.highbeam.com/doc/1G1-92278416.html
(From 2002)

Isonics Corporation (NASDAQ: ISON), a leader in the development of isotopically engineered semiconductor materials and a supplier of silicon-on-insulator wafers and isotopes for life sciences and health care applications, has announced that the company has entered into a multi-year agreement with Eastern Isotopes, Inc., a subsidiary of IBA, for at least $8.8 million, and up to $10.4 million, to supply Oxygen-18, a key raw material in the production of the primary radiopharmaceutical (FDG) for Positron Emission Tomography (PET).